Group 1 - Truist has lowered the price target on Blue Owl Capital (OBDC) to $16 from $17 while maintaining a Buy rating on the shares [1] - The adjustment in the price target is part of a broader research note on Business Development Companies (BDCs) [1] - The firm's model update reflects the company's Q3 results and revised guidance, leading to a reduction in FY25 net interest income per share view by $0.06 to $1.52 [1] Group 2 - The decrease in net interest income per share is attributed to lower assumed interest and fee income, although this is somewhat mitigated by lower incentive fee expenses [1]

Group 1 - BMO Capital analyst Ameet Thakkar raised the price target on Targa Resources (TRGP) to $196 from $185, maintaining an Outperform rating on the shares [1] - The company's Q3 results indicate resilience to lower rig counts and oil prices, which is a positive sign for investors [1] - Expectations for FY26 double-digit volumetric growth and confidence in FY27 may enhance investor sentiment despite challenges in crude/NGL pricing [1]

Summary of Key Points Core Viewpoint - Canaccord analyst George Gianarikas has reduced the price target for Enovix (ENVX) from $22 to $21 while maintaining a Buy rating on the shares, indicating a continued positive outlook despite recent delays in anticipated financial performance [1]. Company Analysis - The recent quarter has introduced another delay in the expected "hockey stick" profit and loss (P&L) trajectory that investors have been anticipating, suggesting that the company may face ongoing challenges in achieving its financial goals [1]. - Investors are advised to remain patient as the company navigates these delays, indicating a long-term investment perspective despite short-term setbacks [1].

Group 1 - JPMorgan raised the price target on Shopify (SHOP) to $180 from $179 while maintaining an Overweight rating on the shares [1] - The increase in price target is attributed to positive estimate revisions following the earnings report [1] - Shopify's volume growth accelerated sequentially in Q3, but there was a spike in transaction losses affecting the Q4 free cash flow margin outlook [1] Group 2 - JPMorgan noted that there has not been a significant change in intra-quarter spending trends for Shopify [1] - The increase in transaction losses is described as "treatable" by the analyst [1]

Summary of Key Points Core Viewpoint - BofA has lowered the price target for Vertex (VERX) to $24 from $34, maintaining a Neutral rating due to a disappointing Q4 outlook [1]. Company Performance - The implied growth rate for Q4 is projected at 9%, which is at the low end of the industry growth range of 8% to 12% [1]. - The firm suggests that the acceleration of growth is dependent on the success of cross-selling the e-invoicing offering [1].

Core Viewpoint - Roth Capital raised the price target on Polaris (PII) to $57 from $54 while maintaining a Neutral rating after the company's Q3 earnings exceeded expectations [1] Group 1: Earnings and Financial Performance - Polaris reported Q3 earnings that beat analyst expectations, contributing to the price target increase [1] Group 2: Market Trends - Retail trends have stabilized in recent months, indicating a positive shift in consumer behavior [1] - Dealer inventories have returned to healthier levels, suggesting improved supply chain conditions [1] Group 3: Concerns and Considerations - The firm remains cautious about incremental elasticity concerns as tariffs are being passed through to consumers across all end markets [1]

Group 1 - UBS analyst Damian Karas has lowered the price target on Lennox (LII) to $560 from $610, maintaining a Neutral rating on the shares [1] - The firm is reducing its estimates by 2%-3% due to persistent headwinds in the residential industry [1]

Core Viewpoint - DA Davidson has lowered the price target for Boise Cascade (BCC) to $95 from $100 while maintaining a Buy rating on the shares, indicating a cautious outlook on the company's performance in the engineered wood products sector [1] Company Summary - The price target for Boise Cascade (BCC) has been adjusted to $95 from $100, reflecting ongoing price pressure in the Engineered Wood Products (EWP) market [1] - Despite the lowered price target, the firm retains a Buy rating on Boise Cascade shares, suggesting confidence in the company's long-term prospects [1] Industry Summary - The Engineered Wood Products (EWP) sector is experiencing continued price pressure, with expectations of low to mid single-digit sequential declines persisting through Q1 [1] - If competition remains intense and prices continue to decline, a significant portion of the EWP industry may operate at or below cash production costs, potentially leading to a supply response [1]

Core Viewpoint - Xcel Energy is positioned as a strong utility company with potential for earnings surprises, supported by recent analyst upgrades and market interest [2][3][6] Company Overview - Xcel Energy (NASDAQ:XEL) provides electricity and natural gas services across multiple states in the U.S., competing with major players like Duke Energy and Southern Company [1] Stock Performance - Morgan Stanley raised its price target for Xcel Energy to $86 from $80, indicating a potential increase of 6.32% from the current stock price of $80.97, which has seen a slight increase of 0.41% [2][6] - The stock has traded between $80.59 and $81.35 on the current day, with a market capitalization of approximately $47.89 billion [4] Earnings Outlook - Zacks Investment Research highlights Xcel Energy for its potential to exceed earnings expectations, suggesting that it could surprise investors in upcoming earnings reports [3][6] - Analysts adjusting earnings estimates may signal potential surprises, making Xcel Energy a stock to watch closely in the utility sector [5]

Core Viewpoint - Truist has raised the price target for Alnylam Pharmaceuticals (ALNY) to $535 from $459 while maintaining a Buy rating ahead of the company's Q3 results [1] Group 1: Sales Estimates - The Q3 sales estimate for Amvuttra has been increased to $690 million [1] - The upward revision in forward estimates reflects strong early adoption and more rapid adoption as a first-line agent than previously expected [1] Group 2: Market Insights - Feedback from prescribers indicates that extracardiac manifestations of ATTR-CM are more widespread than previously appreciated [1]